share_log

Freenome Announces CEO Transition

Freenome Announces CEO Transition

Freenome宣佈首席執行官交接
PR Newswire ·  09/26 01:43

Board of Directors Establishes Interim Office of the CEO and Initiates Search for a Successor to Lead Company Through Next Phase of Development and Commercialization

董事會建立臨時CEO辦公室,並啓動搜索繼任者,帶領公司通過下一階段的發展和商業化

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2024 /PRNewswire/ -- Freenome today announced that Mike Nolan has resigned from his position as chief executive officer (CEO) for personal reasons. The Board of Directors has established an interim Office of the CEO, led by Freenome's co-founder Riley Ennis, with assistance from Douglas VanOort, a Freenome Board member and former chairman of the board and CEO at NeoGenomics, to provide leadership continuity and operational management during the transition. Mr. Nolan will serve as a consultant to the company and its board.

2024年9月25日,加利福尼亞州南舊金山 / PRNewswire -- Freenome今天宣佈,Mike Nolan因個人原因辭去首席執行官(CEO)職務。董事會成立了由Freenome聯合創始人Riley Ennis領導的臨時CEO辦公室,得到Freenome董事會成員、NeoGenomics的前董事長暨首席執行官Douglas VanOort的協助,以在過渡期間提供領導連續性和運營管理。Nolan先生將繼續擔任該公司及其董事會的顧問。

The board will be selecting a successor to guide the organization toward commercialization and increasing its public presence as Freenome focuses on bringing blood-based screening to patients.

董事會將選擇繼任者,引領組織走向商業化,增強Freenome在公衆中的知名度,因爲Freenome專注於爲患者提供基於血液的篩查。

"It has been an honor to work alongside my talented colleagues at Freenome over the past six years," Mr. Nolan said, "I continue to be confident about Freenome's strategic direction and its ability to achieve its goals in the fight against cancer."

「在過去的六年裏,與Freenome傑出的同事們一起工作是我的榮幸,」Nolan先生說,「我對Freenome的戰略方向和公司在與癌症作鬥爭中實現目標的能力仍然充滿信心。」

Randy Scott, Ph.D., CEO at Genomic Life and a Freenome board member since 2017, said, "We are grateful to Mike for his contributions to Freenome throughout his tenure. As CEO, Mike played an important role in Freenome's recent financing and advancing the company's programs. We are in a strong position and wish him all the best."

Genomic Life首席執行官Randy Scott博士,自2017年起擔任Freenome董事會成員,表示:「我們感謝Mike在任期內爲Freenome所做的貢獻。作爲CEO,Mike在Freenome最近的融資和推進公司項目中起到了重要作用。我們目前處於一個強勢位置,祝他一切順利。」

Dr. Scott added, "Freenome is entering an exciting new phase in its mission to detect cancer at its earliest, most treatable stages. The board has full confidence in the company's work to progress the FDA submission of its first blood test following the pivotal PREEMPT CRC results, while continuing to improve its CRC test and advancing into new cancer indications through the ongoing PROACT Lung trial."

Scott博士補充說:「Freenome正在進入一個令人興奮的新階段,致力於在癌症最早、最可治療階段檢測癌症。董事會對公司在進展FDA提交其首個血液檢測的同時,繼續改進其CRC檢測和通過進行中的PROACt肺癌試驗拓展至新的癌症適應症的工作充滿信心。」

About Freenome

關於Freenome

Freenome is breaking barriers to early cancer detection with a suite of blood tests built on its multiomics platform. The company recognizes that no single technology can identify every cancer due to the disease's inherent heterogeneity. Freenome's multimodal approach combines molecular biology and assays with computational biology, machine learning and multiple data types to tune into cancer's subtlest cues, even at the earliest stages of the disease.

Freenome正在打破早期癌症檢測的障礙,基於其多組學平台構建了一套血液檢測。該公司意識到由於疾病固有的異質性,沒有一種技術可以識別每種癌症。Freenome的多模式方法結合了分子生物學和測定與計算生物學、機器學習和多種數據類型,以偵測癌症最微妙的跡象,甚至在疾病的早期階段。

With the convenience of a standard blood draw, Freenome aims to empower everyone to access recommended cancer screenings. The company is partnering with healthcare organizations and population health decision-makers to integrate its technology and software platform, making cancer detection easier and more accessible. Freenome is headquartered in South San Francisco, California. Find out more at and visit us on LinkedIn.

憑藉標準血液檢測的便利性,Freenome旨在賦予每個人獲取推薦癌症篩查的權利。該公司正在與醫療機構和人口健康決策者合作,整合其科技和軟件平台,使癌症檢測更加簡便和可獲得。Freenome總部位於加利福尼亞州南舊金山。欲了解更多信息,請訪問 並訪問我們的 LinkedIn.

SOURCE Freenome Holdings, Inc.

資訊來源:Freenome Holdings, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎?

440k+
440k+

Newsrooms &
新聞發佈室&

Influencers
影響力
9k+
9k+

Digital Media
數字媒體

Outlets
賣場
270k+
270k+

Journalists
新聞記者

Opted In
已選擇加入
GET STARTED
開始使用

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論